Is my portfolio
One Report to Answer all your Questions!
Zydus Lifesciences Ltd.
BSE: 532321 | NSE: ZYDUSLIFE
Mid Cap | Pharmaceuticals & Drugs
903.35
11.80 (1.32%) Zydus Lifesciences informs about press release
Date: 08-04-2026Zydus Lifesciences has informed that it enclosed a copy of press release dated April 8, 2026, titled ‘Zydus receives final approval from USFDA for Dapagliflozin Tablets, 5 mg and 10 mg’.
The above information is a part of company’s filings submitted to BSE.